Ophthalmology Search
Ophthalmology Ophthalmology
blepharitis
BLEPHARITIS
Blepharitis is an inflammation process affecting the eyelid margins, eyelash follicles or openings of the anteriorly-placed accessory lacrimal glands and the posteriorly-placed Meibomian glands that causes ocular irritation and redness acutely but usually chronically.
It may have periods of exacerbations and remissions.
It usually occurs in middle-aged adults but can also start in childhood.
Can affect vision by disrupting the surface of the cornea and the bulbar conjunctiva; may influence tear film composition.

Blepharitis Management

Follow Up

  • Follow-up visits are based on the severity of symptoms & signs, current treatment & comorbid factors
  • Includes interval history, visual acuity measurement, external exam, slit-lamp biomicroscopy, & intraocular pressure (IOP) measurement
  • Patients should be re-evaluated w/in a few weeks to determine the response to therapy & assess compliance to the treatment regimen
  • Prompt referral to an ophthalmologist is recommended if any of the following is observed
    • Visual loss
    • Moderate or severe pain
    • Severe or chronic redness
    • Involvement of the cornea
    • Recurrent episodes
    • Lack of response to treatment
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Carfilzomib-based triplet regimen a potential upfront treatment for high-risk MM
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Alzheimer’s disease prevention: Can antidepressants lend a hand?
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.